RIGL Share Price

Open 2.58 Change Price %
High 2.66 1 Day 0.03 1.15
Low 2.45 1 Week 0.14 5.58
Close 2.65 1 Month -0.06 -2.21
Volume 772272 1 Year -0.52 -16.40
52 Week High 4.38
52 Week Low 0.00
RIGL Important Levels
Resistance 2 2.84
Resistance 1 2.76
Pivot 2.59
Support 1 2.54
Support 2 2.46
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.45 7.29%
MU 20.45 7.29%
MU 20.45 7.29%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ANTH 2.03 38.10%
EMKR 8.45 31.01%
MBLX 0.32 28.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 8.00 23.08%
ATEA 1.95 21.88%
ATEA 1.95 21.88%
More..
NASDAQ USA Top Losers Stocks
DSTI 0.00 -100.00%
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)

RIGL Technical Analysis 4
As on 7th Dec 2016 RIGL Share Price closed @ 2.65 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.68 & Strong Sell for SHORT-TERM with Stoploss of 3.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
RIGL Target for December
1st Target up-side 3.11
2nd Target up-side 3.46
3rd Target up-side 3.82
1st Target down-side 2.09
2nd Target down-side 1.74
3rd Target down-side 1.38
RIGL Other Details
Segment EQ
Market Capital 627448832.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.rigel.com
RIGL Address
RIGL
1180 Veterans Boulevard
South San Francisco, CA 94080
United States
Phone: 650-624-1100
Fax: 650-624-1101
RIGL Latest News
Interactive Technical Analysis Chart Rigel Pharmaceuticals, Inc. ( RIGL NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Rigel Pharmaceuticals, Inc.
RIGL Business Profile
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. As of December 31, 2011, product development programs included fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis (RA) with its partner AstraZeneca (AZ); R343, an inhaled SYK inhibitor for asthma and R333, a topical janus kinase (JAK)/SYK inhibitor for discoid lupusboth of which have commenced Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye. In December 2012, the Company initiated a Phase 1 clinical study of R348, a topical ophthalmic JAK/SYK inhibitor, as a potential therapeutic for chronic dry eye.